We determine phenotypic susceptibility of HIV-2 isolates to amprenavir, atazanavir, darunavir, 32 indinavir, lopinavir, nelfinavir, saquinavir and tipranavir. Saquinavir, lopinavir and darunavir 33 are potent on wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-34 infected patients. Other protease inhibitors are less active on HIV-2 than on HIV-1. 35 36
Few data are available on HIV-2 susceptibility to antiretroviral agents. In France, as 41 recommended by the national expert group on the treatment of HIV infection, HIV-2-infected 42 patients receive highly active antiretroviral therapy (HAART) regimens as HIV-1-infected 43 individuals except non nucleoside reverse transcriptase inhibitors or fusion inhibitors classes 44 (17) (12) . However, a recent study showed that CD4 cell recovery was poor in antiretroviral-45 naive HIV-2 infected patients starting treatment with HAART (8) . Thus it appears crucial to 46 determine HIV-2 susceptibility to the current PIs available, in order to define the optimal 47 regimen to be recommended. 48
We selected nine PI-naive HIV-2-infected patients from the French HIV-2 ANRS cohort. Six of 49 these patients subsequently received HAART regimens including a PI (indinavir, nelfinavir, 50 saquinavir and/or ritonavir) for a median of 13 months (range 2-36), and had plasma viruses 51 harboring mutations in the protease gene. PBMC co-culture isolates were available for these 52 patients before (T0, n=6) and during (T1 (n=6), T2 (n=2)) PI exposure. Protease gene sequences 53 of plasma and PBMC isolates were determined as previously described (3). Amino acid changes 54
were compared with those associated with drug resistance in HIV-1 (International AIDS 55 Society-USA (IAS-USA). We determine the in vitro phenotypic susceptibility of clinical HIV-2 56 isolates and HIV-2 ROD and HIV-1 BRU reference strains to amprenavir, atazanavir, darunavir, 57 indinavir, lopinavir, nelfinavir, saquinavir and tipranavir using the ANRS PBMC assay (4). 58
Phenotypic inhibitory quotients (PIQs) were calculated for each clinical HIV-2 isolate, as the 59 ratio between the trough plasma PI concentration and the IC50. The PIQs were not adjusted for 60
protein binding. The differences were observed at positions involved in but not associated with HIV-1 resistance, median IC50 values of the HIV-2 wild-type isolates were 31-fold higher for amprenavir, 8-fold 68 higher for atazanavir, 7-fold higher for tipranavir, and 3-fold higher for indinavir and nelfinavir. 69
Darunavir, lopinavir and saquinavir IC50 and IC90 values were similar for HIV-1 and the wild-70 type HIV-2 isolates (table). Viruses isolated from the six PI-experienced patients at T1 and T2 71 harboured the I82F, I84V and L90M substitutions, alone or in combination with minor HIV-1 72 PI mutations such as V10I, V33I, I54M, I64V, V71I and I89V. Compared to the corresponding 73 wild-type isolates, the eight mutants showed 4 to >10-fold increases in the IC50 and/or IC90 74 values of all tested PIs, at both T1 and T2. The PIQs values of amprenavir, atazanavir, indinavir, 75 nelfinavir and tipranavir were respectively 33-fold, 8-fold, 3-fold, 3-fold and 7-fold lower for 76
HIV-2 wild-type strains than for HIV-1. Darunavir, lopinavir and saquinavir PIQ values were 77
similar. 78
PIs are designed to fit the active site of the HIV-1 protease and are sensitive to structural 79 changes in the viral protein. It has been reported that the therapeutic outcome of HIV-2-infected 80 patients might be influenced by the choice of PIs (1) (15). For amprenavir our data are in 81 keeping with those reported elsewhere, showing significantly lesser activity against HIV-2 wild-82 type strains than against HIV-1 (9) (14) (16). These phenotypic results could be explained by 83 the natural presence in HIV-2 protease of amino acids associated with resistance to HIV-1, 84 which might influence the binding affinity of the PIs for HIV-2 protease (2) (3) (9) (10) (11). In 85 our study, all the HIV-2 wild-type strains protease sequences naturally presented the amino 86 acids 32I and 47V associated with resistance in HIV-1 infection to amprenavir according to IAS 87 USA list and to different genotypic resistance interpretation algorithms 88 (www.hivfrenchresistance.org,www.hivdb.stanford.edu,www.kuleuven.be/rega/cev/links/rega_a 89 lgorithm). We found that clinical HIV-2 isolates and HIV-1 reference strains had similar 90 phenotypic susceptibility to saquinavir, lopinavir and darunavir. As amprenavir and darunavir 91 are structurally close, we expected darunavir to be relatively ineffective in HIV-2. (6) (7). Moreover, it has been reported in HIV-1 95 that the binding affinity of darunavir for wild-type protease was > 100-fold higher than other PIs 96 due to a slower dissociation rate of this molecule from the protease active site (5). In the same 97 way, crystallography structure studies of the HIV-2 protease and binding affinity experiments 98 might help us to understand the difference observed in the natural susceptibility of HIV-2 strains 99 for these two drugs as well as phenotypic resistance in HIV-2 mutated strains. The IC50 and 100 IC90 values of atazanavir, indinavir, nelfinavir and tipranavir for the HIV-2 isolates were higher 101 than those observed for HIV-1 raising the hypothesis of a lower activity of these PIs against 102
HIV-2. However these values were lower than their respective trough plasma concentrations. 103
This might be explained by the fact that HIV-2 wild-type isolates harbored several amino acids 104 associated with PI resistance in HIV-1. 105 PI treatment-associated amino acid changes in the HIV-2 protease gene occurred at positions 106 known to confer PI resistance in HIV-1 and were not associated with the use of a particular PI 107 without any order of accumulation. They altered the phenotypic susceptibility of the isolates to 108 all the PIs tested here. These results are in keeping with data published elsewhere (2) (3) (9) 109 (11) (13) (15) 
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